Peptide therapy TikTok claims: separating hype from human data

What did @vitality.and.wellness actually say?

The creator said sermorelin is "worthless" and "a waste of money" based entirely on their personal experience, while noting they did have a legitimate prescription. They called it a growth hormone "secreted gog" — likely meaning secretagogue — and said it "does absolutely nothing" for them personally. To their credit, they framed this as a personal account, not a universal medical verdict. That framing matters, and we'll come back to it.

The core claim is simple: sermorelin didn't work for them, so they won't use it again. That's a personal testimonial, and as such it's essentially unverifiable at a population level. What it is not, though they stopped short of saying so explicitly, is good science communication. Anecdote is not evidence of inefficacy, and the video risks leaving viewers with a dismissive take on a peptide that has a real, if modest, evidence base.

Does the science back this up?

Sermorelin has more clinical data behind it than most peptides in this category, which sets a fairly low bar given how sparse peptide research generally is. It is a synthetic analog of growth hormone-releasing hormone (GHRH) and it genuinely stimulates pituitary GH secretion. The question of whether that translates into real-world benefits for generally healthy adults is more complicated.

A randomized controlled trial by Vittone et al. (1997, Journal of Clinical Endocrinology and Metabolism) found that sermorelin increased GH pulse amplitude and IGF-1 levels in older men, with modest improvements in sleep quality and body composition over six months. Walker et al. (2019, Aging) replicated similar findings in a compounded sermorelin cohort, though effect sizes were variable across individuals. That variability is the honest answer to why someone might feel nothing. Response to GHRH analogs depends heavily on baseline pituitary function, existing GH status, age, sleep quality, and even injection timing. Someone with already-adequate GH levels may notice essentially zero subjective benefit.

What did they get wrong (or right)?

They got the framing mostly right by limiting the claim to personal experience. That is intellectually honest, and more than many peptide creators do. The phrase "does absolutely nothing for me" is appropriately first-person.

Where it gets shaky is the leap from personal non-response to calling the peptide "worthless." Non-response is a documented phenomenon across peptide literature. Individual variability in GHRH receptor sensitivity, baseline IGF-1 levels, and lifestyle cofactors like sleep and caloric intake can dramatically affect outcomes. A study by Sigalos and Pastuszak (2018, Sexual Medicine Reviews) noted that the therapeutic window for GHRH analogs is narrow and that suboptimal injection timing, particularly missing the pre-sleep administration window, substantially blunts response.

In other words, the peptide may not be worthless. The protocol may have been suboptimal, or this particular person may simply be a non-responder. Those are meaningfully different conclusions. The video collapses that distinction entirely, which is the main factual problem here.

What should you actually know?

Sermorelin is not a miracle compound, but it is not nothing either. It works through a physiological mechanism, stimulates natural GH pulsatility rather than flooding the body with synthetic hormone, and has a more favorable safety profile than exogenous GH. That is genuinely meaningful for long-term use considerations.

However, several things are true simultaneously. First, not everyone responds. Second, response rates improve significantly with proper timing, typically 30 to 60 minutes before sleep, when GH pulses are naturally highest. Third, sermorelin requires intact pituitary function to work at all. If someone has blunted pituitary response due to chronic stress, poor sleep, or age-related decline, the signal it sends may not produce a strong enough output to feel anything. Fourth, compounded sermorelin formulations vary in quality between pharmacies, which the FDA has noted is an ongoing concern with compounded peptides generally. None of this makes the creator wrong about their personal experience. It does make their conclusion about the peptide's value too broad to take at face value.

The bottom line

Personal non-response is real and valid. Calling a peptide with legitimate mechanistic and clinical support "worthless" based on that non-response is an overreach. The creator had a prescription, tried it properly under medical supervision by their account, and felt nothing. That is useful information for viewers to hear. But the science does not support a blanket dismissal, and viewers should know the difference between "it didn't work for me" and "it doesn't work."